Learn how Aimovig for migraine works, how well it works, what to know before starting, and its possible side effects. Experts and community members also weigh in about their experiences with Aimovig.

JERSEY CITY, NJ, USA I January 30, 2025 I Celltrion today announced that the U.S. Food and Drug Administration (FDA) has approved AVTOZMA® (CT-P47, ...

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 05, 2025(Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodi ...

Zoetis Inc. today announced that it has updated the U.S. label for Librela® (bedinvetmab injection), following its submission of a supplement to the U.S. Food and Drug Administration (FDA). This ...

About PEMGARDA PEMGARDA™ (pemivibart) is a half-life extended investigational monoclonal antibody (mAb). PEMGARDA was engineered from adintrevimab ... PEMGARDA is not authorized for use for treatment ...

UCB, a global biopharmaceutical company, today announced the CHMP (Committee for Medicinal Products for Human Use) has issued a positive opinion for the self-administration of RYSTIGGO® ...

Then, the recombinant A29 protein was used as an antigen to immunize BALB/c mice, and a total of 4 monoclonal antibodies ... sensitivity and specificity. In the future, improvements can be made to the ...

(MENAFN- JCN NewsWire) FDA Approves LEQEMBI (lecanemab-irmb) IV Maintenance Dosing for the treatment ... monoclonal antibody in the setting of focal neurologic symptoms of ARIA and the use of ...

Alzheimer's disease progression does not stop after plaque clearance; ongoing treatment with LEQEMBI can slow disease progression ... Fatal cerebral hemorrhage has occurred in 1 patient taking an anti ...

Genetic variants and clinical factors affecting the response to 5-fluorouracil–based treatment in Chilean patients with advanced colorectal cancer. Sex differences in toxicities and survival outcomes ...

Once every four weeks maintenance dosing may be easier for patients and care partners to continue treatment ... monoclonal antibody in the setting of focal neurologic symptoms of ARIA and the use ...